KCNH2 and cancer: In this scenario, we have generated a TRAIL-based immunoconjugate in which the targeting moiety is represented by a single-chain diabody (scDb-hERG1-β1) directed against two proteins, hERG1 and the β1 integrin, which form a complex in cancer cells (20), fused with three TRAIL sequences which bind to TRAIL receptors (TRAIL-R), hence generating a “trispecific” antibody: scDb-hERG1-β1-TRAIL.